Patent ID: 7625718
Filing Date: 2009-12-01
Classification: A61P,G01N,G06Q,Y10S

Abstract:
1. A method of screening an agent, conjugate, or conjugate moiety for capacity to be transported through the blood brain barrier in order to treat or diagnose a disease, comprising: (a) providing a cell expressing the sodium-dependent vitamin C transporter type 2 (SVCT2), wherein the SVCT2 transporter is the protein encoded by SEQ ID NO: 1 or has at least 90% sequence identity to the protein encoded by SEQ ID NO: 1, and the SVCT2 transporter can transport ascorbic acid, the SVCT2 transporter being situated in the plasma membrane of the cell expressing the SVCT2 transporter; (b) contacting the cell expressing the SVCT2 transporter with an agent, conjugate, or conjugate moiety; (c) determining the V (d) modifying the agent, conjugate or conjugate moiety; and (e) determining the V (f) providing a cell expressing the SVCT2 transporter and at least one efflux transporter or a cell expressing at least one efflux transporter, wherein the at least one efflux transporter is selected from the group consisting of the P-glycoprotein transporter, the multidrug resistance protein transporter, and the breast cancer resistance protein transporter; (g) contacting the cell expressing the SVCT2 transporter and at least one efflux transporter or the cell expressing at least one efflux transporter with the agent, conjugate, or conjugate moiety; and (h) determining that the agent, conjugate, or conjugate moiety is transported by the at least one efflux transporter; and determining the V (i) comparing the ratio of the V wherein: